Skip to main content
OpenTrials
Recruiting

NCT Number: NCT01280825

The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing

The purpose of this study is to collect DNA samples from patients undergoing routine care at the University of Chicago. These samples will be tested for differences in genes that may suggest greater risk of side effects or chance of increased benefit from certain medications. The results will be made available to the patient's treating physician and the researchers will track whether or not this information is used in routine health care.

Recruiting

Interested in participating?

Request Info

Key information

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Receiving ongoing, out-patient care at the University of Chicago Medical Center under the routine care of a physician participating in this trial
  • Life expectancy of at least 3 years
  • Must be 18 years or older
  • Must be taking at least 1 (but not more than 6) prescription medications at the time of enrollment OR be 65 years or older OR be reasonably expected to require the use of a prescription medication within the next 5 years
  • Patients with certain diseases, or likely to receive or be receiving certain drugs, will be targeted particularly for enrollment in order to enrich the study for patients likely to have pharmacogenetically relevant interactions, including, but not limited to:
  • Patients requiring specialized cardiology care
  • Patients with inflammatory bowel diseases
  • Patients with systemic autoimmune or inflammatory diseases
  • Patients requiring long-term oral anticoagulation
  • Patients with hepatitis C
  • Patients with non-metastatic cancer

Exclusion criteria

  • Patients with acute or chronic disease which could be reasonably expected to result in the patient's death within the next 3 years.
  • Patients who have undergone, or are being actively considered for, liver or kidney transplantation.
  • Inability to understand and give informed consent to participate.

Treatment and study plan

Primary outcomes

  1. Feasibility of incorporating pharmacogenomic testing into routine medical care

    Time frame: 5 years

Secondary outcomes

  1. Find out whether availability of pharmacogenomic information impacts drug decision making in the health care setting

    Time frame: 5 years

Other outcomes

  1. To determine whether access to pharmacogenomic information improves satisfaction with care.

    Time frame: 5 years

Study contacts

Contact information is provided by the study sponsor or research team.

1200 Patients Project Study Team

CONTACT

[email protected]

(773) 834-1759

Cancer Clinical Trials Office

CONTACT

[email protected]

1-855-702-8222

Sponsors and collaborators

Lead sponsor

University of Chicago

Other

Registry information

Important dates

Study start
2011
Primary completion
2027
Study completion
2027
First posted
Jan 21, 2011
Registry last updated
Mar 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.